Global Blood Therapeutics Stock News

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the notes) in a private offering (the offering) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act). The offering size was increased from the previously announced offering size of $250.0 million aggregate principal amount of notes. GBT also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $45.0 million aggregate principal amount of notes (the additional notes). The sale of the notes to the initial purchasers is expected to close on December 17, 2021, subject to customary closing conditions, and is expected to result in approximately $290.4 million (or approximately $334.1 million if the initial purchasers exercise their option to purchase additional notes in full) in net proceeds to GBT after deducting the initial purchasers discounts and commissions and the estimated offering expenses payable by GBT.

Investors aren't impressed with the company's latest financing move.

The GLOBAL BLOOD THERAPEUTICS, INC. POLITICAL ACTION COMMITTEE (GBT PAC) successfully filed their F1N with a confirmation ID of FEC-1551570 *********CommitteeId: C00788661 | FilingId: 1551570 | FormType: F1N | CoverageFrom: | CoverageThrough: | ReportType: *********

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). GBT also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of notes (the “additional notes”). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The stock price of Global Blood Therapeutics Inc (NASDAQ: GBT) increased by 5.33% in the most recent trading session. This is why it happened.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) shares saw unusually-high trading volume on Monday . Approximately 31,713 shares changed hands during trading, a decline of 97% from the previous sessions volume of 1,096,170 shares.The stock last traded at $28.00 and had previously closed at $27.59. GBT has been the topic of several research reports. Jefferies Financial Group []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) has received a consensus rating of Buy from the sixteen analysts that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokerages that []

Brokerages predict that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will post sales of $55.05 million for the current fiscal quarter, according to Zacks. Twelve analysts have issued estimates for Global Blood Therapeutics earnings. The highest sales estimate is $58.00 million and the lowest is $53.00 million. Global Blood Therapeutics reported sales of $41.30 million in the []

Invesco Ltd. trimmed its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,920 shares of the companys stock after selling 1,853 shares during the period. Invesco Ltd. owned about 0.06% of Global Blood Therapeutics worth $1,257,000 []

Upgrades For CarMax Inc (NYSE: KMX ), JP Morgan upgraded the previous rating of Neutral to Overweight. For the second quarter, CarMax had an EPS of $1.72, compared to year-ago quarter EPS of $1.79. The stock has a 52-week-high of $155.98 and a 52-week-low of $90.30. At the end of the last trading period, CarMax closed at $144.50. According to Evercore ISI Group, the prior rating for RPM International Inc (NYSE: RPM ) was changed from In-Line to Outperform. In the first quarter, RPM International showed an EPS of $1.08, compared to $1.44 from the year-ago quarter. The current stock performance of RPM International shows a 52-week-high of $99.30 and a 52-week-low of $76.43. Moreover, at the end of the last trading period, the closing price was at $95.43. According to Evercore ISI Group, the prior rating for PPG Industries Inc (NYSE: PPG ) was changed from In-Line to Outperform. In the third quarter, PPG Industries showed an EPS of $1.69, compared to $1.93 from the year-ago quarter. The stock has a 52-week-high of $182.97 and a 52-week-low of $132.10.

Amid the challenging COVID environment, Oxbryta is still generating double-digit sales growth.

Global Blood Therapeutics Inc. (NASDAQ:GBT) traded at $27.98 at close of the session on Monday, 11/29/21, made a downward move of -4.34% on its previous days price. Looking at the stock we see that its previous close was $29.25 and the beta (5Y monthly) reads 1.08 with the days price range being $27.75 $29.79. What Are You Thinking About Investing In Global Blood Therapeutics Inc. (NASDAQ: GBT) Stock? Read More »

Equities research analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report sales of $55.29 million for the current quarter, according to Zacks Investment Research. Twelve analysts have made estimates for Global Blood Therapeutics earnings, with the highest sales estimate coming in at $58.00 million and the lowest estimate coming in at $53.00 million. Global []